Lifecore Biomedical, Inc. (LFCR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 160 | 101 | 111 | 103 | 128 | 129 | 34 | - |
| Operating profit | $m | 3 | - | ||||||
| Net profit | $m | -38 | -32 | -117 | -100 | 12 | -39 | -6 | - |
| EPS reported | $ | -0.19 | - | ||||||
| Operating cashflow per share | $ | 0.38 | - | ||||||
| Capex per share | $ | 0.19 | - | ||||||
| FCF per share | $ | 0.19 | - | ||||||
| Free cash flow | $m | 6 | - | ||||||
| Net debt | $m | 119 | - | ||||||
| Book value equity | $m | -14 | - | ||||||
| Book value per share | $ | -0.38 | - | ||||||
| Number of shares | m | 37.57 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -19.16 | - | ||||||
| P/S LTM | x | 2.10 | - | ||||||
| P/FCF LTM | x | 43.67 | - | ||||||
| EV/EBITDA LTM | x | 48.19 | - | ||||||
| EV/Sales LTM | x | 3.07 | - | ||||||
| Earnings Yield LTM | % | -11.32% | - | ||||||
| FCF Yield | % | +2.29% | - | ||||||
| Quality | |||||||||
| ROE | % | +216.80% | - | ||||||
| ROIC | % | -0.60% | - | ||||||
| Operating margin | % | -0.97% | - | ||||||
| Gross margin | % | +31.37% | - | ||||||
| FCF/Sales | % | +4.81% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -73.49% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | 0.04 | - | ||||||
| Net Debt/EBITDA | x | 15.18 | - | ||||||
| EBIT/Net interest | x | 0.57 | - | ||||||
| Net debt/market cap | % | +50.12% | - | ||||||
| Net debt/Equity | x | -8.37 | - | ||||||
| Gross debt/equity | x | -10.04 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Lifecore Biomedical, Inc. (LFCR)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free